| Author | f/u* (mo’s) | Treatment | n | Breast Failure (%) | Cosmesis | |||
|
|
|
|
| Total | True** | Elsewhere | Good Excellent | |
| Fodor | 120 | WBI |
|
|
|
|
| |
| Arthur [22] | 84 | LDR 45 Gy | 33 | 12% | 10% | 3% | Not stated | |
| RTOG |
| HDR 34Gy | 66 | 3% | 1.5% | 1.5% | ||
| King [16] | 75 | LDR 45 Gy | 26 | 8% | 1% | 3% | 75% | |
| Ochsner Clinic |
| HDR 32 Gy | 26 | |||||
| Vicini [44] [73] [74] | 96 | LDR 50 Gy | 120 | 3% | 1.5% | 1.5% | 99% | |
| William Beaumont | HDR 32 - 34 Gy | 79 | ||||||
| Ott. [20] | 32 | HDR 32 Gy, 4 Gy bid × 8 | 99 |
|
|
|
| |
| German-Austrian | PDR 50 Gy 5days | 175 | 0.7% | <1% | <1% | 94% | ||
| Patel [19] | 49 | Low vs high risk disease | 183 low | 2.2% |
| |||
| Univ. Wisc***** | HDR 32-34 Gy | 90 high | 4.4% | Not available | ||||
| Arthur [40] | 42 | LDR 45 Gy | 13 | 0% | 0% | 0% | 80% | |
| Virg. Commonwealth | HDR 34 Gy | 31 | ||||||
| Kaufman [21] Tufts/Brown Univ | 84 | HDR 34, Gy | 33 | 9% | 6% | 3% | 88% | |
| Lawenda [82] Mass General | 23 | LDR 50-60 Gy | 48 | 0% | 0% | 0% | 92% | |
| Polgar C, et al. [77] NIO Hungary | 81 | HDR 30.3 Gy, 4.33 × 7 |
|
|
|
|
| |
|
| HDR 36.4 Gy, 5.2 Gy × 7 | 45 | 6.7% | 0% | 6.7% | 84% | ||
| HDR 36.4, 5.2 Gy × 7 |
|
|
|
|
| |||
| 83 | Wide-vol electrons 50Gy | 80 | 10% | 3.8% | 6.3% | 68% | ||
| Polgar et al. [77] [78] NIO Hungary Randomized | 67ds | HDR 36.4, 5.2 Gy × 7 |
|
|
|
|
| |
| Limited vo electrons 50 Gy | 128 | 4.7% | 2.3% | 2.3% | 77% | |||
| Whole breast, 50 Gy | 130 | 3% | 1.5% | 1.5% | 69% | |||
| Strnad [79] GEC-ESTRO | 60 | WBI 50.0 - 50.4 Gy/25 - 28 F | 673 | 0.92% | - | - | 63% | |
| with 10Gy/5F boost |
|
|
|
|
| |||
| APBI 32 Gy/8 F or 30.3 Gy/7 F | 675 | 1.44% | - | - | 81% | |||
| Yashar [81] Strut Study | 59.5 | Strut APBI 34 Gy/10 F (twice daily) | 250 | - | 2.3% | 3.6% | 85.9% | |